Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
- Conditions
- Endometrial Neoplasms
- Interventions
- Registration Number
- NCT03884101
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR). It is also hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for overall survival (OS).
As of Amendment 7 eligible participants on study completion will be able to transition to an extension study, if available, in which they can continue to receive pembrolizumab monotherapy, lenvatinib monotherapy, or a combination of both pembrolizumab and lenvatinib as received in the parent study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 842
- Has Stage III, Stage IV, or recurrent, histologically-confirmed endometrial carcinoma with disease that is either measurable or nonmeasurable but radiographically apparent, per RECIST 1.1 as assessed by BICR (note: may have received prior chemotherapy only if administered concurrently with radiation; may have received prior radiation without concurrent chemotherapy; may have received prior hormonal therapy for treatment of endometrial carcinoma, provided that it was discontinued ≥1 week prior to randomization; and may have received 1 prior line of systemic platinum-based adjuvant and/or neoadjuvant chemotherapy)
- Has provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion that was not previously irradiated, for determination of mismatch repair (MMR) status
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, as assessed within 7 days prior to the first dose of study intervention
- Is not pregnant or breastfeeding, and is either not a woman of childbearing potential (WOCBP) or is a WOCBP who agrees to use contraception during the study and for ≥120 days after pembrolizumab, ≥30 days after lenvatinib, or ≥180 days after (chemotherapy) [if a WOCBP, a pregnancy test will be required within 24 hours of first dose of study drug]
- Has adequately controlled blood pressure within 7 days prior to randomization
- Has adequate organ function based on assessment within 7 days prior to the first dose of study intervention
- Has carcinosarcoma (malignant mixed Műllerian tumor), endometrial leiomyosarcoma or other high grade sarcomas, or endometrial stromal sarcomas
- Has a central nervous system (CNS) metastasis, unless local therapy (e.g., whole brain radiation therapy, surgery, or radiosurgery) has been completed and have discontinued use of corticosteroids for this indication for ≥4 weeks prior to starting study medication (major surgery within 3 weeks of the first dose of study drug will be exclusionary)
- Has a known additional malignancy (other than endometrial carcinoma) that is progressing or has required active treatment in the last 3 years
- Has gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib
- Has a pre-existing Grade ≥3 gastrointestinal or nongastrointestinal fistula
- Has radiographic evidence of major blood vessel invasion/infiltration
- Has active hemoptysis (bright red blood at ≥0.5 teaspoon) within 3 weeks prior to the first dose of study intervention or tumor bleeding within 2 weeks prior to randomization
- Has clinically significant cardiovascular disease within 12 months from first dose of study intervention including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction or cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability
- Has any infection requiring systemic treatment
- Has not recovered adequately from any toxicity and/or complications from major surgery prior to randomization
- Has a known history of human immunodeficiency virus (HIV) infection (HIV test is required at screening)
- Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (HCV) [defined as HCV ribonucleic acid (RNA) is detected] (hepatitis B and C testing is required at screening only when mandated by local health authority)
- Has a history of (noninfectious) pneumonitis that required treatment with steroids, or has current pneumonitis
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
- Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization
- Has an active autoimmune disease (with the exception of psoriasis) that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs)
- Has received prior systemic chemotherapy in any setting for the treatment of endometrial carcinoma (note: prior chemotherapy administered concurrently with radiation is permitted)
- Has received prior radiotherapy within 4 weeks prior to randomization (participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis - a 2-week washout is permitted for palliative radiation to non-CNS disease and vaginal brachytherapy)
- Has received prior hormonal therapy for the treatment of endometrial carcinoma within 1 week of randomization
- Has received prior therapy with any treatment targeting vascular endothelial growth factor (VEGF)-directed angiogenesis, an anti-programmed cell death (PD)-1, anti-PD ligand (L)1, or anti-PD L2 agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137)
- Has received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention
- Has known intolerance to study intervention (or any of the excipients)
- Has had an allogenic tissue/solid organ transplant
- Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to randomization
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Lenvatinib + Pembrolizumab Lenvatinib Participants receive lenvatinib daily and pembrolizumab once at the start of each 3-week treatment cycle. Paclitaxel + Carboplatin Carboplatin Participants receive paclitaxel and carboplatin once at the start of each 3-week treatment cycle. Paclitaxel + Carboplatin Paclitaxel Participants receive paclitaxel and carboplatin once at the start of each 3-week treatment cycle. Lenvatinib + Pembrolizumab Pembrolizumab Participants receive lenvatinib daily and pembrolizumab once at the start of each 3-week treatment cycle.
- Primary Outcome Measures
Name Time Method Progression-free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants Up to approximately 44 months PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The PFS of pMMR participants was presented.
PFS Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants Up to approximately 44 months PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The PFS of all randomized participants was presented.
Overall Survival (OS) in pMMR Participants Up to approximately 51 months OS was measured from the time of randomization up to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. The OS for pMMR participants is presented.
OS in All Randomized Participants Up to approximately 51 months OS was measured from the time of randomization up to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. The OS for all randomized participants is presented.
- Secondary Outcome Measures
Name Time Method Objective Response Rate (ORR) Based on RECIST 1.1 as Assessed by BICR in pMMR Participants Up to approximately 51 months ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of pMMR participants who experienced a CR or PR is presented.
ORR Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants Up to approximately 51 months ORR was defined as the percentage of participants who had a CR: Disappearance of all target lesions or a PR: At least a 30% decrease in the sum of diameters of target lesions as assessed using RECIST 1.1. The percentage of all randomized participants who experienced a CR or PR is presented.
Mean Change From Baseline in the Global Health Status/Quality of Life Score of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30) in pMMR Participants Baseline and up to approximately 18 weeks The EORTC QLQ-C30 was developed to assess the quality of life of patients with cancer. It contains 30 questions (items), 24 of which aggregate into nine multi-item scales representing various aspects, or dimensions, of quality of life (QoL): one global scale, five functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea, pain), and six additional single-symptom items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhoea) and perceived financial impact of the disease. Individual items are scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Raw scores for each scale are standardized into a range of 0 to 100 by linear transformation; a higher score on the global and functional scales represents a higher ("better") level of functioning, and a higher score on the symptom scale represents a higher ("worse") level of symptoms.
Mean Change From Baseline in the Global Health Status/Quality of Life Score of the EORTC QLQ-C30 in All Randomized Participants Baseline and up to approximately 18 weeks The EORTC QLQ-C30 was developed to assess the quality of life of patients with cancer. It contains 30 questions (items), 24 of which aggregate into nine multi-item scales representing various aspects, or dimensions, of QoL: one global scale, five functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea, pain), and six additional single-symptom items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhoea) and perceived financial impact of the disease. Individual items are scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Raw scores for each scale are standardized into a range of 0 to 100 by linear transformation; a higher score on the global and functional scales represents a higher ("better") level of functioning, and a higher score on the symptom scale represents a higher ("worse") level of symptoms.
Percentage of Participants Experiencing an Adverse Event (AE) Up to approximately 27 months (through 90 days after the last dose of study treatment) An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Percentage of Participants Experiencing a Serious Adverse Event (SAE) Up to approximately 28 months (through 120 days after the last dose of study treatment) An SAE is an AE that results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or significant disability, is a congenital birth defect, or is another important medical event.
Percentage of Participants Experiencing an Immune-Related AE (irAE) Up to approximately 27 months (through 90 days after the last dose of study treatment) Immune-related AEs will be monitored in both arms.
Percentage of Participants Discontinuing From Study Treatment Due to an AE(s) Up to approximately 24 months (through the last dose of study treatment) Discontinuations related to AEs will be monitored in both arms.
Trial Locations
- Locations (195)
UCLA Hematology and Oncology Clinic (Westwood) ( Site 0233)
🇺🇸Los Angeles, California, United States
University of Rochester ( Site 0238)
🇺🇸Rochester, New York, United States
Faculdade de Medicina da Universidade Federal de Minas Gerais ( Site 2708)
🇧🇷Belo Horizonte, Minas Gerais, Brazil
University of Miami Health System ( Site 0249)
🇺🇸Miami, Florida, United States
Roger Maris Cancer Center ( Site 0277)
🇺🇸Fargo, North Dakota, United States
Ospedale Antonio Perrino ( Site 0806)
🇮🇹Brindisi, Italy
Memorial Sloan-Kettering Cancer Center At Basking Ridge ( Site 0268)
🇺🇸Basking Ridge, New Jersey, United States
Arizona Oncology Associates PC- HOPE ( Site 8005)
🇺🇸Tucson, Arizona, United States
Sanford Cancer Center Oncology Clinic ( Site 0205)
🇺🇸Sioux Falls, South Dakota, United States
MSKCC-Bergen ( Site 0276)
🇺🇸Montvale, New Jersey, United States
Hospital Italiano de La Plata ( Site 2601)
🇦🇷La Plata, Buenos Aires, Argentina
Cork University Hospital ( Site 1400)
🇮🇪Cork, Ireland
Ospedale dell Angelo ( Site 0810)
🇮🇹Mestre, Venezia, Italy
Holy Name Medical Center ( Site 0235)
🇺🇸Teaneck, New Jersey, United States
Princess Margaret Cancer Centre ( Site 0409)
🇨🇦Toronto, Ontario, Canada
Medizinische Universitat Innsbruck ( Site 3302)
🇦🇹Innsbruck, Tirol, Austria
CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0414)
🇨🇦Montreal, Quebec, Canada
McGill University Health Centre ( Site 0404)
🇨🇦Montreal, Quebec, Canada
Universitaetsklinikum Essen ( Site 0616)
🇩🇪Essen, Nordrhein-Westfalen, Germany
Universitaetsklinikum Jena ( Site 0612)
🇩🇪Jena, Thuringen, Germany
Cross Cancer Institute ( Site 0408)
🇨🇦Edmonton, Alberta, Canada
Willamette Valley Cancer Institute and Research Center ( Site 8004)
🇺🇸Eugene, Oregon, United States
Cliniques Universitaires Saint-Luc ( Site 3203)
🇧🇪Brussels, Bruxelles-Capitale, Region De, Belgium
AZ Maria Middelares Gent ( Site 3202)
🇧🇪Gent, Oost-Vlaanderen, Belgium
Universitaetsklinikum Muenster ( Site 0615)
🇩🇪Muenster, Baden-Wurttemberg, Germany
HELIOS Dr. Horst Schmidt Kliniken Wiesbaden ( Site 0623)
🇩🇪Wiesbaden, Hessen, Germany
Medical Oncology Ospedale San Donato ( Site 0812)
🇮🇹Arezzo, Italy
Ospedale Policlinico S. Orsola-Malpighi ( Site 0803)
🇮🇹Bologna, Italy
Women's Cancer Care ( Site 0208)
🇺🇸Covington, Louisiana, United States
Hospital San Lucas Cardiologica del Sureste ( Site 3103)
🇲🇽Tuxtla Gutierrez, Chiapas, Mexico
Consultorio Dentro de la Torre Medica Dalinde Oncologia Medica ( Site 3108)
🇲🇽Ciudad de Mexico, Mexico
National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 1103)
🇷🇺Saint-Petersburg, Sankt-Peterburg, Russian Federation
John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0226)
🇺🇸Hackensack, New Jersey, United States
Maine Medical Partners ( Site 0217)
🇺🇸Scarborough, Maine, United States
Mater Misericordiae Ltd ( Site 1608)
🇦🇺South Brisbane, Queensland, Australia
Monash Health ( Site 1606)
🇦🇺Clayton, Victoria, Australia
Juravinski Cancer Centre ( Site 0406)
🇨🇦Hamilton, Ontario, Canada
IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 2607)
🇦🇷Caba, Buenos Aires, Argentina
Medizinische Universitat Wien ( Site 3300)
🇦🇹Vienna, Wien, Austria
UZA University Hospital Antwerp ( Site 3204)
🇧🇪Edegem, Antwerpen, Belgium
Hospital Araujo Jorge Associacao de Combate ao Cancer de Goias ( Site 2702)
🇧🇷Goiania, Goias, Brazil
A.C. Camargo Cancer Center ( Site 2705)
🇧🇷Sao Paulo, Brazil
Universitaetsmedizin Mannheim. Klinik fuer Kinder und Jugendmedizin ( Site 0622)
🇩🇪Mannheim, Baden-Wurttemberg, Germany
University of the Ryukyus Hospital ( Site 2412)
🇯🇵Nakagami-gun, Okinawa, Japan
Kingston Health Sciences Centre ( Site 0401)
🇨🇦Kingston, Ontario, Canada
The Credit Valley Hospital ( Site 0403)
🇨🇦Mississauga, Ontario, Canada
Instituto de Investigaciones Clinicas Mar del Plata ( Site 2606)
🇦🇷Mar del Plata, Buenos Aires, Argentina
Hospital Aleman ( Site 2600)
🇦🇷Buenos Aires, Argentina
Universitatsklinik fuer Frauenheilkunde und Geburtshilfe ( Site 3301)
🇦🇹Graz, Steiermark, Austria
UZ Leuven ( Site 3200)
🇧🇪Leuven, Antwerpen, Belgium
Epworth Freemasons Hospital ( Site 1609)
🇦🇺Melbourne, Victoria, Australia
Instituto Nacional do Cancer II ( Site 2707)
🇧🇷Rio de Janeiro, Brazil
Clinica de Pesquisas e Ctro de Estudos Onc. Ginecol. e Mamaria Ltda ( Site 2706)
🇧🇷Sao Paulo, Brazil
Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 2713)
🇧🇷Sao Paulo, Brazil
IRCCS Giovanni Paolo II. Ospedale Oncologico ( Site 0801)
🇮🇹Bari, Italy
Istituto Nazionale Tumori Fondazione Pascale ( Site 0808)
🇮🇹Napoli, Italy
Gunma Prefectural Cancer Center ( Site 2404)
🇯🇵Ota, Gunma, Japan
BC Cancer-Vancouver Center ( Site 0412)
🇨🇦Vancouver, British Columbia, Canada
BC Cancer-Kelowna - Sindi Ahluwalia Hawkins Centre ( Site 0402)
🇨🇦Kelowna, British Columbia, Canada
Charite Universitaetsmedizin Berlin ( Site 0609)
🇩🇪Berlin, Germany
Chaim Sheba Medical Center ( Site 0707)
🇮🇱Ramat Gan, Israel
Azienda Ospedaliera per l Emergenza Cannizzaro ( Site 0807)
🇮🇹Catania, Italy
I CAN Oncology SA de SV ( Site 3102)
🇲🇽Monterrey, Nuevo Leon, Mexico
Centro Oncologico Internacional. SEDNA ( Site 3106)
🇲🇽Mexico City, Mexico
Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie ( Site 1008)
🇵🇱Lublin, Dolnoslaskie, Poland
Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1108)
🇷🇺Kazan, Tatarstan, Respublika, Russian Federation
Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 1507)
🇺🇦Kyiv, Kyivska Oblast, Ukraine
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0800)
🇮🇹Meldola, Emilia-Romagna, Italy
National Hospital Organization Hokkaido Cancer Center ( Site 2408)
🇯🇵Sapporo, Hokkaido, Japan
Saitama Medical University International Medical Center ( Site 2410)
🇯🇵Hidaka, Saitama, Japan
Showa University Hospital ( Site 2419)
🇯🇵Tokyo, Japan
SPb SBHI City Clinical Oncological Dispensary ( Site 1104)
🇷🇺Saint Petersburg, Sankt-Peterburg, Russian Federation
Linkou Chang Gung Memorial Hospital ( Site 1901)
🇨🇳Taoyuan, Taiwan
National Defense Medical College Hospital ( Site 2418)
🇯🇵Tokorozawa, Saitama, Japan
Keio University Hospital ( Site 2411)
🇯🇵Tokyo, Japan
Wielkopolskie Centrum Onkologii im.M.Sklodowskiej-Curie ( Site 1004)
🇵🇱Poznan, Wielkopolskie, Poland
Krasnoyarsk Regional Clinical oncology dispensary ( Site 1118)
🇷🇺Krasnoyarsk, Krasnoyarskiy Kray, Russian Federation
Russian Oncological Research Center n.a. N.N.Blokhin of MoH ( Site 1100)
🇷🇺Moscow, Moskva, Russian Federation
FSBI-FRCC of Special Types Med. Care and Technologies FMBA of Russia ( Site 1102)
🇷🇺Moscow, Moskva, Russian Federation
Taichung Veterans General Hospital ( Site 1902)
🇨🇳Taichung, Taiwan
MI Odessa Regional Oncological Centre ( Site 1504)
🇺🇦Odesa, Odeska Oblast, Ukraine
Asan Medical Center ( Site 1800)
🇰🇷Seoul, Korea, Republic of
Osaka International Cancer Institute ( Site 2409)
🇯🇵Osaka, Japan
St.Petersburg Clinical Hospital RAS ( Site 1124)
🇷🇺Saint Petersburg, Sankt-Peterburg, Russian Federation
Railway Hospital of OJSC ( Site 1122)
🇷🇺Saint-Petersburg, Sankt-Peterburg, Russian Federation
Siberian State Medical University ( Site 1121)
🇷🇺Tomsk, Tomskaya Oblast, Russian Federation
Cukurova Uni. Tip Fakultesi ( Site 1302)
🇹🇷Adana, Turkey
Kyiv City Clinical Oncology Centre ( Site 1505)
🇺🇦Kyiv, Ukraine
MI Precarpathian Clinical Oncology Center ( Site 1503)
🇺🇦Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine
Baskent Universitesi Ankara Hastanesi ( Site 1300)
🇹🇷Ankara, Turkey
Communal non profit enterprise Regional Clinical Oncology Center ( Site 1509)
🇺🇦Kharkiv, Kharkivska Oblast, Ukraine
University of South Alabama, Mitchell Cancer Institute ( Site 0245)
🇺🇸Mobile, Alabama, United States
Georgia Cancer Center at Augusta University ( Site 0222)
🇺🇸Augusta, Georgia, United States
Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0273)
🇺🇸Middletown, New Jersey, United States
Memorial Sloan Kettering Cancer Center - West Harrison ( Site 0274)
🇺🇸Harrison, New York, United States
The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0206)
🇺🇸New York, New York, United States
Memorial Sloan-Kettering Cancer Center at Commack ( Site 0267)
🇺🇸Commack, New York, United States
Memorial Sloan Kettering Cancer Center ( Site 0246)
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center - Nassau ( Site 0275)
🇺🇸Uniondale, New York, United States
Legacy Salmon Creek Medical Center ( Site 0253)
🇺🇸Vancouver, Washington, United States
University of Texas Southwestern Medical Center ( Site 0264)
🇺🇸Dallas, Texas, United States
Parkland Health & Hospital System ( Site 0272)
🇺🇸Dallas, Texas, United States
Hospital Italiano de Buenos Aires ( Site 2603)
🇦🇷Buenos Aires, Argentina
Centro Oncologico Riojano Integral ( Site 2605)
🇦🇷La Rioja, Argentina
Chris OBrien Lifehouse ( Site 1605)
🇦🇺Camperdown, New South Wales, Australia
Prince of Wales Hospital [Australia] ( Site 1603)
🇦🇺Randwick, New South Wales, Australia
Royal North Shore Hospital ( Site 1600)
🇦🇺St Leonards, New South Wales, Australia
The Crown Princess Mary Cancer Centre - Westmead Hospital ( Site 1602)
🇦🇺Westmead, New South Wales, Australia
Sir Charles Gairdner Hospital ( Site 1604)
🇦🇺Nedlands, Western Australia, Australia
Hospital de Caridade de Ijui ( Site 2712)
🇧🇷Ijui, Rio Grande Do Sul, Brazil
AZ Delta ( Site 3206)
🇧🇪Roeselare, West-Vlaanderen, Belgium
Instituto do Cancer do Ceara ( Site 2703)
🇧🇷Fortaleza, Ceara, Brazil
Hospital de Base de Sao Jose de Rio Preto ( Site 2704)
🇧🇷Sao Jose do Rio Preto, Sao Paulo, Brazil
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 2701)
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0411)
🇨🇦Montreal, Quebec, Canada
Anhui Provincial Cancer Hospital ( Site 2509)
🇨🇳Hefei, Anhui, China
Beijing Obstetrics and Gynecology Hospital Capital Medical University ( Site 2505)
🇨🇳Beijing, Beijing, China
Peking Union Medical College Hospital ( Site 2501)
🇨🇳Beijing, Beijing, China
Chongqing Cancer Hospital ( Site 2513)
🇨🇳Chongqing, Chongqing, China
Guang Xi Tumour Hospital, Department of Chemotherapy ( Site 2517)
🇨🇳Nanning, Guangxi, China
Beijing Cancer Hospital ( Site 2504)
🇨🇳Beijing, Beijing, China
Hubei Cancer Hospital ( Site 2510)
🇨🇳Wuhan, Hubei, China
Nanjing Maternity and Child Health Care Hospital ( Site 2508)
🇨🇳Nanjing, Jiangsu, China
The First Affiliated Hospital.Sun Yat-sen University ( Site 2507)
🇨🇳Guangzhou, Guangdong, China
The first affiliated Hospital of Xi an Jiaotong University ( Site 2502)
🇨🇳XI An, Shaanxi, China
Fudan University Shanghai Cancer Center ( Site 2500)
🇨🇳Shanghai, Shanghai, China
Xiangya Hospital Central-South University ( Site 2512)
🇨🇳Changsha, Hunan, China
The First Affiliated Hospital of Xinjiang Medical University ( Site 2515)
🇨🇳Urumqi, Xinjiang, China
Caritas-Krankenhaus St. Josef Regensburg ( Site 0613)
🇩🇪Regensburg, Bayern, Germany
Women s Hospital School of Medicine Zhejiang University ( Site 2511)
🇨🇳Hangzhou, Zhejiang, China
Obstetrics and Gynecology Hosp. Fudan University ( Site 2503)
🇨🇳Shanghai, Shanghai, China
Zhejiang Cancer Hospital ( Site 2506)
🇨🇳Hangzhou, Zhejiang, China
St James Hospital ( Site 1401)
🇮🇪Dublin, Ireland
Edith Wolfson Medical Center ( Site 0703)
🇮🇱Holon, Tell Abib, Israel
Meir Medical Center ( Site 0702)
🇮🇱Kfar-Saba, Central, Israel
Rambam Medical Center ( Site 0700)
🇮🇱Haifa, Israel
Policlinico Universitario Agostino Gemelli ( Site 0805)
🇮🇹Rome, Roma, Italy
Ehime University Hospital ( Site 2413)
🇯🇵Toon, Ehime, Japan
Kurume University Hospital ( Site 2403)
🇯🇵Kurume, Fukuoka, Japan
Nippon Medical School Musashi Kosugi Hospital ( Site 2417)
🇯🇵Kawasaki, Kanagawa, Japan
Hyogo Cancer Center ( Site 2414)
🇯🇵Akashi, Hyogo, Japan
St. Marianna University School of Medicine Hospital ( Site 2416)
🇯🇵Kawasaki, Kanagawa, Japan
Saitama Cancer Center ( Site 2406)
🇯🇵Kitaadachi-gun, Saitama, Japan
Kyorin University Hospital ( Site 2402)
🇯🇵Mitaka, Tokyo, Japan
Niigata Cancer Center Hospital ( Site 2415)
🇯🇵Niigata, Japan
National Hospital Organization Kyushu Cancer Center ( Site 2405)
🇯🇵Fukuoka, Japan
The Cancer Institute Hospital of JFCR ( Site 2401)
🇯🇵Tokyo, Japan
Seoul National University Bundang Hospital ( Site 1802)
🇰🇷Seongnam-si, Kyonggi-do, Korea, Republic of
Severance Hospital Yonsei University Health System ( Site 1804)
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center ( Site 1803)
🇰🇷Seoul, Korea, Republic of
Centro de Investigacion Clinica Gramel ( Site 3107)
🇲🇽Mexico City, Mexico
Centro Estatal de Cancerologia de Chihuahua ( Site 3101)
🇲🇽Chihuahua, Mexico
Instytut Centrum Zdrowia Matki Polki ( Site 1020)
🇵🇱Lodz, Lodzkie, Poland
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 1019)
🇵🇱Krakow, Malopolskie, Poland
Szpital Kliniczny im Ks Anny Mazowieckiej ( Site 1011)
🇵🇱Warszawa, Mazowieckie, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1009)
🇵🇱Warsaw, Mazowieckie, Poland
Bialostockie Centrum Onkologii ( Site 1005)
🇵🇱Bialystok, Podlaskie, Poland
Centrum Onkologii Instytut im. MSC Oddział w Gliwicach ( Site 1017)
🇵🇱Gliwice, Slaskie, Poland
Samara Regional Clinical Oncology Center ( Site 1117)
🇷🇺Samara, Samarskaya Oblast, Russian Federation
Medical Rehabilitation Center ( Site 1101)
🇷🇺Moscow, Moskva, Russian Federation
Institut Catala d Oncologia Badalona ( Site 1201)
🇪🇸Badalona, Barcelona, Spain
Instituto Valenciano de Oncologia - IVO ( Site 1205)
🇪🇸Valencia, Valenciana, Comunitat, Spain
Complejo Hospitalario Universitario A Coruna. CHUAC ( Site 1202)
🇪🇸A Coruna, La Coruna, Spain
Hospital General Universitario de Valencia ( Site 1203)
🇪🇸Valencia, Valenciana, Comunitat, Spain
Parc de Salut Mar ( Site 1200)
🇪🇸Barcelona, Spain
Hospital Clinico San Carlos ( Site 1209)
🇪🇸Madrid, Spain
Hospital Universitario Reina Sofia ( Site 1207)
🇪🇸Cordoba, Spain
National Taiwan University Hospital ( Site 1904)
🇨🇳Taipei, Taiwan
China Medical University Hospital ( Site 1903)
🇨🇳Taichung, Taiwan
Hospital Materno Infantil [Malaga, Spain] ( Site 1208)
🇪🇸Malaga, Spain
Taipei Veterans General Hospital ( Site 1900)
🇨🇳Taipei, Taiwan
Baskent Universitesi Adana Uygulama ve Arastirma Hastanesi ( Site 1303)
🇹🇷Adana, Turkey
Uludag Universitesi Tip Fakultesi ( Site 1307)
🇹🇷Bursa, Turkey
Gazi Universitesi Tip Fakultesi ( Site 1308)
🇹🇷Ankara, Turkey
Akdeniz Universitesi Tıp Fakultesi ( Site 1301)
🇹🇷Antalya, Turkey
City Clinical Hosp.4 of DCC ( Site 1501)
🇺🇦Dnipro, Dnipropetrovska Oblast, Ukraine
Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 1511)
🇺🇦Kharkiv, Kharkivska Oblast, Ukraine
Khmelnitskiy Regional Onkology Dispensary ( Site 1513)
🇺🇦Khmelnitskiy, Khmelnytska Oblast, Ukraine
Medical Center Asklepion LLC ( Site 1514)
🇺🇦Khodosivka, Kyivska Oblast, Ukraine
National Cancer Institute of the MoH of Ukraine ( Site 1510)
🇺🇦Kyiv, Kyivska Oblast, Ukraine
Western General Hospital ( Site 1411)
🇬🇧Edinburgh, Edinburgh, City Of, United Kingdom
UCLH NHS Foundation Trust ( Site 1405)
🇬🇧London, London, City Of, United Kingdom
Mount Vernon Cancer Centre ( Site 1409)
🇬🇧Northwood, London, City Of, United Kingdom
Churchill Hospital ( Site 1406)
🇬🇧Oxford, Oxfordshire, United Kingdom
The James Cook University Hospital ( Site 1403)
🇬🇧Middlesbrough, United Kingdom
Northern Centre for Cancer Care ( Site 1408)
🇬🇧Newcastle Upon Tyne, United Kingdom
Texas Oncology-The Woodlands ( Site 8000)
🇺🇸The Woodlands, Texas, United States
Sunnybrook Research Institute ( Site 0410)
🇨🇦Toronto, Ontario, Canada
CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0417)
🇨🇦Sherbrooke, Quebec, Canada
Seoul National University Hospital ( Site 1801)
🇰🇷Seoul, Korea, Republic of
Minnesota Oncology Hematology, PA ( Site 8003)
🇺🇸Minneapolis, Minnesota, United States
University of Colorado Cancer Center ( Site 0204)
🇺🇸Aurora, Colorado, United States
University of North Carolina- Chapel Hill ( Site 0254)
🇺🇸Chapel Hill, North Carolina, United States
Smilow Cancer Hospital at Yale New Haven ( Site 0202)
🇺🇸New Haven, Connecticut, United States
Clinical oncology dispensary of Dnipro ( Site 1512)
🇺🇦Dnipro, Dnipropetrovska Oblast, Ukraine